Furthermore, the extent of correlation of CSF1 with immune checkpoint genes was in concert with recent data implicating CSF1 as a CD8+ T-cell-dependent adaptive resistance mechanism to PD-1 blockade and showing that simultaneous CSF1R targeting may be beneficial in melanomas refractory to ICB (47). This evidence concerns the gene PDCD1 and melanoma.